Please assess the completion status of the following clinical trial:

Trial Title: Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Prior allogeneic hematopoietic stem cell transplant using either bone marrow, peripheral blood stem cells, or cord blood~* De novo acute GVHD diagnosed within 48 hours prior to enrollment; biopsy confirmation of GVHD is strongly recommended but not required; enrollment should not be delayed awaiting biopsy or pathology results; the patient must have had no previous systemic immune suppressive therapy given for treatment of acute GVHD except for a maximum 48 hours of prior corticosteroid therapy (at least 1 mg/kg/day methylprednisolone)~* Patients that have undergone a scheduled donor lymphocyte infusion (DLI) as part of their original transplant therapy plan~* Absolute neutrophil count (ANC) greater than 500/µL~* Clinical status at enrollment to allow tapering of steroids to not less than 1 mg/kg/day methylprednisolone (1.4 mg/kg/day prednisone) at Day 28 of therapy (e.g., persisting malignant disease suggesting the need for accelerated taper of immunosuppression)~* Estimated creatinine clearance greater than 30 mL/minute~* Assent and educational materials provided to, and reviewed with, patients under the age of 18~Exclusion Criteria:~* ONTAK, pentostatin, or etanercept given within 7 days of enrollment~* Active uncontrolled infection~* Patients that have undergone an unscheduled DLI, or DLI that was not part of their original transplant therapy plan~* If any prior steroid therapy (for indication other than GVHD), treatment at doses of at least 0.5 mg/kg/day methylprednisolone within 7 days prior to onset of GVHD~* Patients unlikely to be available at the transplant center on Day 28 and 56 of therapy~* A clinical syndrome resembling de novo chronic GVHD developing at any time after allotransplantation (see Chapter 2 of the BMT CTN Manual of Procedures for details of de novo chronic GVHD)~* Other investigational therapeutics for GVHD within 30 days, including agents used for GVHD prophylaxis~* Patients who are pregnant, breast feeding, or if sexually active, unwilling to use effective birth control for the duration of the study~* Adults unable to provide informed consent~* Patients with a history of intolerance to any of the study drugs

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Etanercept (Type: EXPERIMENTAL): Enroll within 48 hours of new onset acute GVHD and randomize to Etanercept
- Mycophenolate Mofetil (Type: EXPERIMENTAL): Enroll within 48 hours of new onset acute GVHD and randomize to Mycophenolate Mofetil
- Denileukin Diftitox (Type: EXPERIMENTAL): Enroll within 48 hours of new onset acute GVHD and randomize to Denileukin Diftitox
- Pentostatin (Type: EXPERIMENTAL): Enroll within 48 hours of new onset acute GVHD and randomize to Pentostatin

Based on this trial design, predict the completion outcome and termination type (if applicable).